More off-label scrutiny on the horizon

According to a press release:

    A senior attorney from the HHS OIG this month warned that in the wake of Pfizer's $430 mln settlement, more off-label investigations are on the way. Meanwhile, a federal prosecutor says that as many as 100 qui tam suits have been filed against the pharmaceutical industry, reports the Sept 27 2004 issue of Rx Compliance Report...With increasing money spent on drugs will come increasing scrutiny of conduct in sales, warns [Asst US Atty Michael Loucks]. "The two go hand-in-hand."

Anyone else sense "a perfect storm" of regulation, scrutiny, and legal actions in the wind? Is CME still a "safe harbor," or do we need to start looking for emergency shelters to ride out the potential off-label storm?

To comment on this post, click on "comments" below. To receive a weekly update, e-mail Sue.

Hide comments

Comments

  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Publish